Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

ABSTRACT:

SUBMITTER: Coens C 

PROVIDER: S-EPMC5636622 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature